[1] [1] HUANG J J, DENG Y Y, BOAKYE D, et al. Global distribution, risk factors, and recent trends for cervical cancer: a worldwide country-level analysis[J]. Gynecol Oncol, 2022, 164(1): 85-92.

[2] [2] SINGH D, VIGNAT J, LORENZONI V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative[J]. Lancet Glob Health, 2023, 11(2): e197-e206.

[3] [3] LIU L, WANG A H, LIU X L, et al. Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer[J]. J Transl Med, 2022, 20(1): 280.

[4] [4] SHARMA P, GOSWAMI S, RAYCHAUDHURI D, et al. Immune checkpoint therapy-current perspectives and future directions[J]. Cell, 2023, 186(8): 1652-1669.

[5] [5] LORUSSO D, XIANG Y, HASEGAWA K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial[J]. Lancet, 2024, 403(10434): 1341-1350.

[6] [6] OAKNIN A, MOORE K, MEYER T, et al. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial[J]. Lancet Oncol, 2024, 25(5): 588-602.

[7] [7] TREFNY M P, KIRCHHAMMER N, DER MAUR P A, et al. Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy[J]. Nat Commun, 2023, 14(1): 86.

[8] [8] PHILIP M, SCHIETINGER A. CD8+ T cell differentiation and dysfunction in cancer[J]. Nat Rev Immunol, 2022, 22(4): 209-223.

[9] [9] CHEN J, SONG Y, MIAO F, et al. PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8+ T cell exhaustion during metastasis[J]. Cancer Sci, 2021, 112(9): 3437-3454.

[10] [10] BAI R L, LV Z, XU D S, et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors[J]. Biomark Res, 2020, 8: 34.

[11] [11] MAKUKU R, KHALILI N, RAZI S, et al. Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy[J]. J Immunol Res, 2021, 2021: 6661406.

[12] [12] WANG Y Z, WANG J S, DU J, et al. Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review[J]. Front Immunol, 2024, 15: 1305810.

[13] [13] LEE J B, KHAN D H, HURREN R, et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production[J]. Blood, 2021, 138(3): 234-245.

[14] [14] WEI W, CHEN Z N, WANG K. CRISPR/Cas9: a powerful strategy to improve CAR-T cell persistence[J]. Int J Mol Sci, 2023, 24(15): 12317.

[15] [15] NIU H Y, WANG H Q. TOX regulates T lymphocytes differentiation and its function in tumor[J]. Front Immunol, 2023, 14: 990419.

[16] [16] AHMAD A, ANSARI I A. Carvacrol exhibits chemopreventive potential against cervical cancer cellsviacaspase-dependent apoptosis and abrogation of cell cycle progression[J]. Anticancer Agents Med Chem, 2021, 21(16): 2224-2235.

[17] [17] FENG X, SHAN R, HU X M. The linkage of NF-B signaling pathway-associated long non-coding RNAs with tumor microenvironment and prognosis in cervical cancer[J]. BMC Med Genomics, 2023, 16(1): 169.

[18] [18] WANG D J, ZOU F, LI Y, et al. Targeting MELK improves PD-1 blockade efficiency in cervical cancerviaenhancing antitumor immunity[J]. Mol Ther Oncol, 2024, 32(1): 200759.

[19] [19] BORST J, BUSSELAAR J, BOSMA D M T, et al. Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy[J]. Eur J Immunol, 2021, 51(8): 1911-1920.

[20] [20] BUDIMIR N, THOMAS G D, DOLINA J S, et al. Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade[J]. Cancer Immunol Res, 2022, 10(2): 146-153.

[21] [21] CILLO A R, CARDELLO C, SHAN F, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity[J]. Cell, 2024, 187(16): 4373-4388.e15.

[22] [22] ECKER M, SCHREGLE R, KAPOOR-KAUSHIK N, et al. SNX9-induced membrane tubulation regulates CD28 cluster stability and signalling[J]. eLife, 2022, 11: e67550.